Abstract
Pulmonary embolism is a common medical problem and although many patients have a benign clinical course there is still appreciable morbidity and mortality associated with the diagnosis. It is generally accepted that thrombolysis is the treatment of choice in patients with haemodynamic compromise but the management of haemodynamically stable patients with large pulmonary embolism is less well defined. A significant proportion of this latter group have a complicated hospital course and require escalation of therapy. There is increasing interest in markers that can potentially identify at risk patients who would benefit from intensive monitoring and therapy. Conversely these markers would also identify low risk patients who could be managed on an outpatient basis alone. This article reviews the current evidence for the use of the clinical history and examination, electrocardiogram, echocardiography, computed tomography and cardiac biochemical markers, principally troponin and brain natriuretic peptide, for risk stratification in pulmonary embolism.
Keywords: Pulmonary embolism, risk, stratification, BNP, pro-BNP, CT, troponin, echocardiogram, electrocardiogram
Current Respiratory Medicine Reviews
Title: Risk Stratification in Pulmonary Embolism
Volume: 1 Issue: 3
Author(s): Mark Weatherhead and George Antunes
Affiliation:
Keywords: Pulmonary embolism, risk, stratification, BNP, pro-BNP, CT, troponin, echocardiogram, electrocardiogram
Abstract: Pulmonary embolism is a common medical problem and although many patients have a benign clinical course there is still appreciable morbidity and mortality associated with the diagnosis. It is generally accepted that thrombolysis is the treatment of choice in patients with haemodynamic compromise but the management of haemodynamically stable patients with large pulmonary embolism is less well defined. A significant proportion of this latter group have a complicated hospital course and require escalation of therapy. There is increasing interest in markers that can potentially identify at risk patients who would benefit from intensive monitoring and therapy. Conversely these markers would also identify low risk patients who could be managed on an outpatient basis alone. This article reviews the current evidence for the use of the clinical history and examination, electrocardiogram, echocardiography, computed tomography and cardiac biochemical markers, principally troponin and brain natriuretic peptide, for risk stratification in pulmonary embolism.
Export Options
About this article
Cite this article as:
Weatherhead Mark and Antunes George, Risk Stratification in Pulmonary Embolism, Current Respiratory Medicine Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339805774598027
DOI https://dx.doi.org/10.2174/157339805774598027 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Update on the Cardiac Safety of Moxifloxacin
Current Drug Safety Refined Echocardiographic Assessment and Contemporary Medical Treatment of Obstructive Hypertrophic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Novel Applications for Invasive and Non-invasive Tools in the Era of Contemporary Percutaneous Coronary Revascularisation
Current Cardiology Reviews “Impact of Smoking Cessation Treatment” on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study
Recent Patents on Anti-Cancer Drug Discovery GHB Pharmacology and Toxicology: Acute Intoxication, Concentrations in Blood and Urine in Forensic Cases and Treatment of the Withdrawal Syndrome
Current Neuropharmacology Hypoxia Inducible Factor-1α, Endothelial Progenitor Cells, Monocytes,Cardiovascular Risk, Wound Healing, Cobalt and Hydralazine:A Unifying Hypothesis
Current Drug Targets Hematocrit-lowering Effect Following Inactivation of Renin-Angiotensin System with Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
Current Topics in Medicinal Chemistry Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets Ghrelin and the Brain-gut Axis as a Pharmacological Target for Appetite Control
Current Pharmaceutical Design The ACE2-Ang-(1-7)-Mas Axis and Cardioprotection
Current Cardiology Reviews Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Therapeutic Angiogenesis in Ischemic Tissues by Growth Factors and Bone Marrow Mononuclear Cells Administration: Biological Foundation and Clinical Prospects
Current Stem Cell Research & Therapy Potential Impact of MicroRNA-423 Gene Variability in Coronary Artery Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pulmonary Hypertension: Current Therapy and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Can PPARγ Ligands Be Used in Cancer Therapy?
Current Medicinal Chemistry - Anti-Cancer Agents Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design Cytoprotection by Natural and Synthetic Polyphenols in the Heart: Novel Mechanisms and Perspectives
Current Pharmaceutical Design Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets Gender Disparity in Lipid Target Achievements in High and Very High Atherosclerotic Cardiovascular Disease Risk Patients in the Arabian Gulf
Current Vascular Pharmacology